Top 5 Pharma Mutual Funds of 2026: One Fund Delivered 28.61% in 3 Years — Did You Miss the Healthcare Rally?
Healthcare is no longer just a defensive sector. In 2026, it has become one of the most compelling growth stories in the Indian equity market, and savvy investors are finally taking notice. Pharma mutual funds, once considered niche instruments suited only for sector specialists, have quietly delivered some of the most jaw-dropping three-year and five-year returns in the entire mutual fund universe. If you have been sitting on the fence, wondering whether to invest in this space, this in-depth guide is built specifically for you.
Over the past three years, the Indian pharmaceutical sector has been powered by a convergence of powerful tailwinds — from a robust export pipeline to the United States, strong domestic formulation demand, biosimilar growth opportunities, and even geopolitical factors that briefly disrupted but ultimately validated India’s role as the “pharmacy of the world.” For context, when the U.S. administration’s reciprocal tariff announcements rattled broader markets, Indian pharma stocks actually surged nearly 5 percent in a single session as pharmaceutical products were exempted from those tariffs — a moment that underscored just how structurally important this sector has become.
Against this backdrop, five pharma mutual funds in India have risen to the top, each offering investors distinct risk-return profiles, expense structures, and portfolio strategies. Let us walk through all five, starting with the one that leads the pack by a significant margin.
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund
If one fund embodies the healthcare rally of the last three years, it is the ICICI Prudential Pharma Healthcare and Diagnostics Fund, popularly known as the P.H.D. Fund. It currently holds the top position among all pharma-focused mutual funds in India with a staggering 3-year annualised return of 28.61% and a 5-year return of 21.16%. This is not a small-margin victory. It leads its closest competitor by over 170 basis points on the 3-year metric — a meaningful outperformance when compounded over time.
The fund’s strategy is notably broader than a pure-play pharma fund. As its name suggests, it extends into healthcare services and diagnostics — segments like hospital chains, diagnostic labs, and specialty healthcare providers that were massively under-owned before the post-pandemic healthcare awareness wave. This diversification has been a key alpha generator. The fund carries an AUM of approximately Rs 6,801 crore, reflecting strong and growing investor confidence. The fund’s Total Expense Ratio (TER) of 1.11% is moderate for its category, making it reasonably cost-efficient relative to the alpha it generates.
For investors wondering whether the 28.61% return is an anomaly, it is worth noting that the fund has also outperformed on a 5-year basis, meaning this performance is not a flash-in-the-pan event tied to one good year — it reflects a sustained, disciplined investment approach by the ICICI Prudential AMC fund management team.
SBI Healthcare Opportunities Fund
Right behind the frontrunner is the SBI Healthcare Opportunities Fund, delivering a 26.87% annualised return over 3 years and 20.66% over 5 years. This fund is one of the oldest healthcare-focused funds in India, having been in existence since December 2004, and that longevity gives it a depth of track record that newer entrants simply cannot match.
With an AUM of approximately Rs 3,313 crore and a TER of 0.97%, the SBI Healthcare Opportunities Fund is one of the more cost-effective options in this category. A lower expense ratio directly translates to better net returns in your pocket over the long term, and at sub-1%, this fund offers institutional-grade cost efficiency for retail investors. The fund has a well-diversified portfolio within healthcare, with meaningful allocations to large-cap pharmaceutical majors as well as mid-cap specialty players.
One of the fund’s standout characteristics is its risk-adjusted performance. It has consistently outperformed its benchmark, delivering 25.21% over three years against a benchmark return of 24.76%, and 16.10% over five years against the benchmark’s 15.08%. While the absolute margin may appear thin, consistent benchmark outperformance over multi-year periods is the hallmark of a well-managed active fund. For conservative investors looking for their first foray into pharma sector funds, SBI Healthcare Opportunities Fund is often the starting point financial advisors recommend.
UTI Healthcare Fund
The UTI Healthcare Fund rounds out the top three with a 25.94% 3-year return and 18.81% over 5 years, positioning it as a strong mid-field performer in a competitive category. Managed by UTI AMC, one of India’s oldest and most trusted asset management companies, this fund benefits from institutional credibility and a time-tested investment process. The fund has been operational since August 1, 2005, making it one of the most seasoned healthcare-focused funds in the country.
The UTI Healthcare Fund carries an AUM of approximately Rs 1,057 crore and a TER of 1.22%, which is slightly higher than the SBI offering. However, the broader UTI brand and the fund’s consistent long-term performance make it a credible choice for investors seeking stability within the sector. The fund has delivered 1-year returns of approximately 19%, indicating that short-term momentum continues to align with long-term performance trends.
One aspect that makes UTI Healthcare Fund particularly interesting is its portfolio construction philosophy, which blends both formulation companies and healthcare infrastructure plays. In a year where domestic healthcare spending continues to increase as India’s middle class expands and health insurance penetration grows, this balanced approach could be a structural advantage. Investors in the UTI fund benefit from the added comfort of dealing with one of India’s most regulated and transparent fund houses.
Tata India Pharma & Healthcare Fund
The Tata India Pharma and Healthcare Fund occupies the fourth spot with 24.52% over 3 years and 19.26% over 5 years, and it deserves more attention than it typically receives in mainstream financial media. Managed by Tata Asset Management, a fund house celebrated for its disciplined risk management, this fund has built a reputation for avoiding concentrated bets and maintaining a well-hedged portfolio across sub-sectors of healthcare.
With an AUM of approximately Rs 1,104 crore and a TER of just 0.74% — the second-lowest in this list — the Tata India Pharma and Healthcare Fund offers one of the best value propositions in the category when cost-efficiency is weighed against returns. A TER of 0.74% means investors retain more of their gains compared to higher-expense competitors, an advantage that compounds meaningfully over a 7-10 year holding period.
The fund has posted 1-year returns of approximately 14.33%, which while lower than peers on short-term metrics, is consistent with its more conservative approach to stock selection. Investors who prioritise downside protection and are looking to build a core healthcare allocation over 5-10 years will find the Tata offering to be one of the more prudent choices on this list.
DSP Healthcare Fund
Closing the top five is the DSP Healthcare Fund with 24.13% over 3 years and 19.37% over 5 years. Managed by DSP Mutual Fund, a well-respected boutique AMC known for its research-intensive investment philosophy, this fund stands out for arguably the most attractive expense structure in the entire pharma fund category. Its TER of just 0.63% is the lowest among the top five, making it exceptionally cost-efficient.
The fund manages an AUM of approximately Rs 2,951 crore, reflecting strong institutional confidence despite its relatively lower 1-year return of 12.76% compared to peers. This short-term underperformance should not be read as a red flag — DSP Healthcare Fund’s longer-horizon numbers remain highly competitive, and its 5-year return of 19.37% actually exceeds that of both UTI and SBI Healthcare funds. The slightly lower 1-year number reflects DSP’s preference for quality businesses at reasonable valuations rather than chasing momentum.
For long-term investors — those thinking in terms of 7 to 10 years and beyond — the DSP Healthcare Fund’s combination of low cost, quality focus, and strong 5-year track record makes it one of the most compelling structural bets in the pharma space.
Why Has the Healthcare Sector Outperformed?
Understanding the “why” behind these exceptional returns is essential for making an informed investment decision. Three primary structural drivers have powered India’s healthcare sector rally.
The U.S. Generic Export Opportunity: India supplies approximately 40% of all generic drugs consumed in the United States. When the U.S. government exempted pharmaceutical products from reciprocal tariffs in early 2025, it validated India’s irreplaceable role in global medicine supply chains. This news sent the CNX Pharma Index to its best single-day performance in over four years and renewed investor appetite for pharma funds across the board.
Domestic Demand Acceleration: India’s domestic formulation market is growing at a compounded double-digit rate, driven by rising chronic disease prevalence (diabetes, hypertension, cancer), improved health insurance coverage, and government schemes like Ayushman Bharat. This creates a dual-engine growth story — exporters benefiting from global demand while domestic players ride India’s own healthcare consumption boom.
Biosimilars and Specialty Pharmaceuticals: Indian pharma companies are aggressively investing in biologics and biosimilars, which represent the next generation of high-value medicines. Companies like Sun Pharma, Dr. Reddy’s, Cipla, and Divis Laboratories — which feature prominently in most of these mutual funds’ top holdings — are building pipelines that could generate significantly higher margins than generic small molecules. This R&D investment is already beginning to reflect in earnings, which in turn drives fund NAVs higher.
A Snapshot of the Top 5 Funds
2026 Pharma Fund Performance at a Glance
| Fund Name | 3-Year Return | 5-Year Return | AUM (Approx.) | TER |
|---|---|---|---|---|
| ICICI Pru Pharma P.H.D Fund | 28.61% | 21.16% | Rs 6,801 cr | 1.11% |
| SBI Healthcare Opportunities Fund | 26.87% | 20.66% | Rs 3,313 cr | 0.97% |
| UTI Healthcare Fund | 25.94% | 18.81% | Rs 1,057 cr | 1.22% |
| Tata India Pharma & Healthcare Fund | 24.52% | 19.26% | Rs 1,104 cr | 0.74% |
| DSP Healthcare Fund | 24.13% | 19.37% | Rs 2,951 cr | 0.63% |
Should You Invest Now? Key Considerations
This is the question every prospective investor is asking in May 2026, and the answer is nuanced. Sector funds, by their very nature, carry concentration risk — their fate is tied to one industry’s fortunes. Pharma funds are no exception. Regulatory headwinds from the U.S. FDA, currency fluctuations affecting export revenues, drug price controls in India, and competition from global generics manufacturers are all risks that cannot be overlooked.
That said, several indicators suggest the healthcare sector’s structural growth story remains intact. India’s healthcare spending as a percentage of GDP is still significantly below the global average, meaning there is a long runway of catch-up growth ahead. The government’s Production Linked Incentive (PLI) scheme for pharmaceuticals continues to attract massive capital investment. And with an ageing global population increasingly dependent on medicine, demand is only expected to grow.
From a portfolio construction standpoint, financial advisors generally recommend that sector funds like pharma funds should not exceed 10-15% of your total equity portfolio. They work best as a satellite allocation layered on top of a diversified core portfolio of large-cap or flexi-cap funds. If you are a new investor, starting with a Systematic Investment Plan (SIP) in one of these funds allows you to average your cost of acquisition over time, reducing the risk of entering at a market peak.
For investors with a 5-10 year horizon and a tolerance for moderate volatility, the pharma sector offers one of the clearest structural investment thesis in the Indian equity market today. The funds ranked above have demonstrated not just strong returns but also consistent management quality, disciplined portfolio construction, and institutional-grade risk controls.
The Verdict: Which Fund Should You Choose?
There is no one-size-fits-all answer, but a framework helps clarify the decision. If you want the highest-performing fund with the broadest healthcare mandate including diagnostics, the ICICI Prudential Pharma P.H.D Fund is the clear leader. If cost-efficiency and benchmark-beating consistency matter more than absolute return ranking, the SBI Healthcare Opportunities Fund strikes the best balance. If you are highly cost-sensitive and think in decade-long time horizons, the DSP Healthcare Fund at 0.63% TER is hard to beat structurally. For investors who want the safety of an established brand with disciplined risk management, the Tata India Pharma and Healthcare Fund deserves serious consideration. And for those who trust the institutional depth of a heritage AMC like UTI, the UTI Healthcare Fund provides both credibility and competitive returns.
The healthcare rally is not over. It may have delivered extraordinary three-year numbers, but the underlying fundamentals — export growth, domestic demand, biosimilar pipelines, and government policy support — suggest that this sector has years of compounding ahead. The real question is not whether you missed the rally. The real question is whether you will act before the next leg begins.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial or investment advice. Mutual fund investments are subject to market risks. Past performance is not indicative of future results. Please consult a SEBI-registered investment advisor before making investment decisions.
